Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial: Journal of Clinical Oncology

R.T. Penson, R.V. Valencia, D. Cibula, N. Colombo, III Leath C.A., M. Bidzinski, J.-W. Kim, J.H. Nam, R. Madry, C. Hernández, P.A.R. Mora, S.Y. Ryu, T. Milenkova, E.S. Lowe, L. Barker, G. Scambia

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): A randomized phase III trial: Journal of Clinical Oncology'. Together they form a unique fingerprint.

Medicine & Life Sciences